|
Oct 10
|
Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit
|
|
Oct 4
|
Immutep concludes participant enrolment in Phase II breast cancer trial
|
|
Oct 3
|
Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer
|
|
Sep 24
|
Immutep Receives A$3.6 million R&D Tax Incentive from French Government
|
|
Aug 14
|
Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody
|
|
Jul 31
|
Immutep Quarterly Activities Report Q4 FY24
|
|
Jun 25
|
Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer
|
|
May 15
|
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024
|
|
May 2
|
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
|
|
Apr 29
|
Immutep Quarterly Activities Report Q3 FY24
|
|
Apr 24
|
Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?
|
|
Apr 24
|
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
|
|
Apr 18
|
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
|
|
Apr 17
|
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
|
|
Mar 27
|
Immutep Limited (ASX:IMM): Is Breakeven Near?
|
|
Mar 24
|
11 Best ASX Stocks To Buy Now
|
|
Mar 5
|
Immutep Announces First Clinical Data from 90mg Dosing of Efti
|
|
Dec 21
|
Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
|
|
Dec 7
|
Immutep Receives A$2.6 million R&D Tax Incentive from French Government
|
|
Nov 27
|
Immutep (ASX:IMM) investors are sitting on a loss of 22% if they invested five years ago
|